https://wikimd.org/index.php?action=history&feed=atom&title=WAY-267464 2026-04-27T02:39:10Z Revision history for this page on the wiki MediaWiki 1.44.2 https://wikimd.org/index.php?title=WAY-267464&diff=5809274&oldid=prev 2024-05-22T17:46:01Z

<p>CSV import</p> <p><b>New page</b></p><div>[[File:WAY-267464.svg|thumb|WAY-267464.svg]] &#039;&#039;&#039;WAY-267464&#039;&#039;&#039; is a chemical compound that acts as a selective [[serotonin 5-HT6 receptor]] antagonist. It has been studied for its potential effects on [[cognition]] and [[memory]], making it of interest in the field of [[neuropsychopharmacology]].<br /> <br /> ==Chemical Properties==<br /> WAY-267464 is characterized by its selective binding affinity to the [[5-HT6 receptor]], a subtype of the [[serotonin receptor]] family. The chemical structure and properties of WAY-267464 contribute to its specificity and efficacy in modulating [[serotonin]] activity in the brain.<br /> <br /> ==Pharmacology==<br /> As a 5-HT6 receptor antagonist, WAY-267464 inhibits the action of serotonin at this specific receptor site. This inhibition can lead to various downstream effects, including the enhancement of [[neurotransmitter]] release such as [[acetylcholine]], [[dopamine]], and [[glutamate]]. These neurotransmitters play crucial roles in cognitive processes, suggesting that WAY-267464 may have potential therapeutic applications in treating cognitive deficits.<br /> <br /> ==Potential Therapeutic Uses==<br /> Research has indicated that WAY-267464 may have potential in the treatment of [[Alzheimer&#039;s disease]], [[schizophrenia]], and other cognitive disorders. By improving neurotransmitter function, it may help alleviate symptoms associated with these conditions, such as memory loss and impaired cognitive function.<br /> <br /> ==Research and Development==<br /> Studies on WAY-267464 are ongoing, with preclinical trials showing promising results in animal models. Further research is needed to determine its efficacy and safety in humans. The development of WAY-267464 is part of a broader effort to explore the therapeutic potential of 5-HT6 receptor antagonists in neuropsychiatric conditions.<br /> <br /> ==See Also==<br /> * [[Serotonin receptor]]<br /> * [[Neurotransmitter]]<br /> * [[Cognition]]<br /> * [[Memory]]<br /> * [[Alzheimer&#039;s disease]]<br /> * [[Schizophrenia]]<br /> <br /> ==References==<br /> {{Reflist}}<br /> <br /> ==External Links==<br /> {{No external links}}<br /> <br /> [[Category:Serotonin receptor antagonists]]<br /> [[Category:Neuropsychopharmacology]]<br /> [[Category:Experimental drugs]]<br /> <br /> {{medicine-stub}}</div>

Prab